The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 07, 2023

Filed:

Mar. 07, 2022
Applicants:

Universitat Zurich, Zurich, CH;

Universitat Basel, Basel, CH;

Inventors:
Assignees:

UNIVERSITÄT ZÜRICH, Zurich, CH;

UNIVERSITÄT BASEL, Basel, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07K 14/74 (2006.01); A61K 39/395 (2006.01); A61P 31/22 (2006.01); A61P 31/18 (2006.01); A61P 31/16 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70539 (2013.01); A61K 39/395 (2013.01); A61K 48/00 (2013.01); A61P 31/16 (2018.01); A61P 31/18 (2018.01); A61P 31/22 (2018.01); A61P 35/00 (2018.01); C07K 2319/00 (2013.01); Y02A 50/30 (2018.01);
Abstract

The invention relates to MHC-Ia open conformers as immunomodulatory agents, particularly in the treatment or prevention of cancer. The open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-heavy chain from the MHC-Ia molecules. The open conformer further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the MHC-Ia open conformers and immune checkpoint inhibitors. Furthermore, the invention relates to the use of MHC-Ia open conformers as immunomodulators, particularly in diseases where the interaction to diverse immunoregulatory receptors such as KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, LILRB2, and PTPRJ modulates an immune response, and in diseases were the negative modulation of Tregs is a therapeutic strategy, e.g. infectious diseases.


Find Patent Forward Citations

Loading…